API | famitinib

famitinib Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Chemistry

SMILES: CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
InChIKey: GKEYKDOLBLYGRB-LGMDPLHJSA-N
Mol. Mass: 410.49
ALogP: 3.3 Partition coefficient
ChEMBL Molecules:

famitinib

famitinib

More Chemistry

Pharmacology

Mechanisms of Action:
- Platelet-derived growth factor receptor alpha (Homo sapiens) ^UniProt
- Platelet-derived growth factor receptor beta (Homo sapiens) ^UniProt
- Mast/stem cell growth factor receptor Kit (Homo sapiens) ^UniProt
- Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens) ^UniProt
- Vascular endothelial growth factor receptor 1 (Homo sapiens) ^UniProt
- Vascular endothelial growth factor receptor 2 (Homo sapiens) ^UniProt
- Vascular endothelial growth factor receptor 3 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

5-(2-(diethylamino)ethyl0-2-9(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl)-3-methyl-6,7-dihydro-1h-pyrrolo(3,2-c)pyridin-4(5h)-one | famitinib | famitinib malate | shr1020 | shr-1020 | shr10201

Organizations (11)

Research & Development (11)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (23)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (23)

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Cholangiocarcinoma (Phase 2)

Colorectal Neoplasms (Phase 3)

Endometrial Neoplasms (Phase 2)

Esophageal Squamous Cell Carcinoma (Phase 2)

Gastrointestinal Stromal Tumors (Phase 3)

Healthy Volunteers (Phase 1)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 1/Phase 2)

Melanoma (Phase 2)

Nasopharyngeal Carcinoma (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Pharmacokinetics (Phase 1/Phase 2)

Sezary Syndrome (Phase 2)

Small Cell Lung Carcinoma (Phase 3)

Thyroid Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 3)

Uterine Cervical Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 52
# of Trial Organizations: 11

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue